Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN-001 Plus TNT in Locally Advanced Rectal Cancer
NCT05079503Unknown
- Sponsor
- Korean Cancer Study Group
- Start
- Dec 2021
- Primary completion
- Aug 2023
- Modality
- Live Biotherapeutic Products
01
Overview
Open-label, single-arm trial of LR20011 in locally advanced rectal cancer (LARC), sponsored by Korean Cancer Study Group. Primary endpoints: Dynamic change of gut microbiome: a-diversity index at 30 weeks, Dynamic change of gut microbiome: b-diversity index at 30 weeks and 2 more. Status: unknown.
02
Drugs
LR20011
03
Conditions
locally advanced rectal cancer (LARC)
Beyond the preview
Go deeper on NCT05079503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079503.